Business Description
Intellia Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US45826J1051
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.27 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.23 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.48 | |||||
Beneish M-Score | 8.79 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -26.6 | |||||
3-Year EBITDA Growth Rate | -34.8 | |||||
3-Year EPS without NRI Growth Rate | -31.2 | |||||
3-Year FCF Growth Rate | -68.8 | |||||
3-Year Book Growth Rate | 12.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 2.1 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 76.88 | |||||
9-Day RSI | 63.71 | |||||
14-Day RSI | 55.38 | |||||
6-1 Month Momentum % | 3.44 | |||||
12-1 Month Momentum % | -44.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Days Sales Outstanding | 78.65 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12 | |||||
Shareholder Yield % | -6.27 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -983.45 | |||||
Net Margin % | -922.94 | |||||
FCF Margin % | -775.74 | |||||
ROE % | -44.79 | |||||
ROA % | -37.09 | |||||
ROIC % | -127.33 | |||||
ROC (Joel Greenblatt) % | -332.34 | |||||
ROCE % | -42.17 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 42.84 | |||||
PB Ratio | 2.27 | |||||
Price-to-Tangible-Book | 2.27 | |||||
EV-to-EBIT | -3.25 | |||||
EV-to-Forward-EBIT | -2.95 | |||||
EV-to-EBITDA | -3.29 | |||||
EV-to-Forward-EBITDA | -3 | |||||
EV-to-Revenue | 31.92 | |||||
EV-to-Forward-Revenue | 39.98 | |||||
EV-to-FCF | -4.12 | |||||
Price-to-Net-Current-Asset-Value | 3.23 | |||||
Price-to-Net-Cash | 3.23 | |||||
Earnings Yield (Greenblatt) % | -30.77 | |||||
FCF Yield % | -17.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Intellia Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 52.604 | ||
EPS (TTM) ($) | -5.36 | ||
Beta | -0.18 | ||
Volatility % | 61.11 | ||
14-Day RSI | 55.38 | ||
14-Day ATR ($) | 0.940789 | ||
20-Day SMA ($) | 22.46065 | ||
12-1 Month Momentum % | -44.78 | ||
52-Week Range ($) | 19.37 - 46.91 | ||
Shares Outstanding (Mil) | 96.48 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Intellia Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Intellia Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Intellia Therapeutics Inc Frequently Asked Questions
What is Intellia Therapeutics Inc(LTS:0JBU)'s stock price today?
When is next earnings date of Intellia Therapeutics Inc(LTS:0JBU)?
Does Intellia Therapeutics Inc(LTS:0JBU) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |